Mast cell activation syndrome

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors

Retrieved on: 
Monday, January 8, 2024

WASHINGTON, Jan. 8, 2024 /PRNewswire/ -- KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announced today entry into an amended exclusive licensing agreement with Georgetown University to advance the development of novel tyrosine kinase inhibitor (TKI) chemical entities (NCE) for the treatment of multiple disease indications. The amendment provides an extension of the exclusively licensed rights to these four novel chemical entities for the treatment of new disease conditions including inflammatory, mast-cell associated diseases, and oncology, in addition to existing rights in neurodegenerative diseases. KeifeRx is currently conducting optimizing and IND-enabling studies involving four separate formulations of the TKI (renamed KFRX03, KFRX04, KFRX05, and KFRX06) with patent life through 2037.

Key Points: 
  • The amendment provides an extension of the exclusively licensed rights to these four novel chemical entities for the treatment of new disease conditions including inflammatory, mast-cell associated diseases, and oncology, in addition to existing rights in neurodegenerative diseases.
  • KeifeRx is currently conducting optimizing and IND-enabling studies involving four separate formulations of the TKI (renamed KFRX03, KFRX04, KFRX05, and KFRX06) with patent life through 2037.
  • "We look forward to working with the research team at Georgetown University to spearhead the development of KFRX03, KFRX04, KFRX05, and KFRX06 for the treatment of multiple, underserved disease indications.
  • The IP covering these assets extends through 2037, making the portfolio a high-value drug opportunity given its numerous potential disease indications, including Alzheimer's disease, ALS, mast cell activation syndrome (MCAS), and urticaria."

SOLVE M.E. LAUNCHES THE FIRST NATIONWIDE PSA CAMPAIGN TO BROADEN AWARENESS OF LONG COVID

Retrieved on: 
Wednesday, August 17, 2022

LOS ANGELES, Aug. 15, 2022 /PRNewswire/ -- Solve M.E. has released the first nationwide public service announcement (PSA) campaign titled "How Long?" to broaden awareness of Long Covid and highlight the need for more research to adequately help the many patients affected by this debilitating disease, which could last a lifetime.

Key Points: 
  • has released the first nationwide public service announcement (PSA) campaign titled " How Long? "
  • has released a PSA campaign to broaden awareness of Long Covid and highlight the need for more research.
  • Over 20 million Americans are suffering from Long Covid , and Long Covid could account for 15% of the nation's unfilled jobs.
  • campaign, support our work to solve Long Covid and associated conditions, learn more about participating in research, and join our advocacy efforts.

Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury

Retrieved on: 
Tuesday, April 19, 2022

NEW YORK, April 19, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company is adding a new asset to its pipeline portfolio, HT-TBI, which is based on scientific research performed by Hoth. HT-TBI is being developed as a novel, point-of-care therapy for the treatment of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI"). HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.

Key Points: 
  • HT-TBI is being developed as a novel, point-of-care therapy for the treatment of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI").
  • TBIs occur due to physical or mechanical trauma to the brain but are also associated with secondary brain injury (e.g., fluid/swelling, inflammation, oxidative damage, etc.).
  • The statistics of patients permanently impacted by stroke and TBI is astounding and Hoth is driven to reduce that burden."
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.

Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference

Retrieved on: 
Tuesday, April 12, 2022

NEW YORK, April 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced acceptance to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 – August 4, 2022 in San Diego, California. The presentation will include results from cognitive and behavioral studies currently underway with HT-ALZ using an APP/PS1 mouse model.

Key Points: 
  • NEW YORK, April 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced acceptance to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 August 4, 2022 in San Diego, California.
  • Dr. Carla Yuede, lead researcher on the HT-ALZ sponsored research agreement with Washington University , will be the primary author presenting the data.
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.
  • Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes.

Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention

Retrieved on: 
Friday, April 1, 2022

NEW YORK, April 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company will be presenting at the BIO International Convention taking place June 13 - 16, 2022 in San Diego, California.

Key Points: 
  • Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease Therapeutic
    NEW YORK, April 1, 2022 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company will be presenting at the BIO International Convention taking place June 13 - 16, 2022 in San Diego, California.
  • Dr. Stefanie Johns, Chief Scientific Officer, will be presenting an overview of the Hoth Therapeutics pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's disease therapeutic under development.
  • To learn more about the BIO International Convention or register to attend, visit the conference website .
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.

Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation

Retrieved on: 
Wednesday, February 16, 2022

Atlas Venture founded and seeded Third Harmonic Bio in 2019 and co-led the $50 million Series A with OrbiMed with participation from BVF Partners.

Key Points: 
  • Atlas Venture founded and seeded Third Harmonic Bio in 2019 and co-led the $50 million Series A with OrbiMed with participation from BVF Partners.
  • Additional new investors in the round included Boxer Capital, RA Capital, RTW, Deep Track Capital, Ajax Health/Zeus, and Commodore Capital.
  • Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation.
  • Visit ThirdHarmonicBio.com or follow us on Twitter or LinkedIn to learn more about our work, our team, and our culture.

Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients

Retrieved on: 
Wednesday, February 9, 2022

With its rich dermatological heritage, NUVISAN France specializes in innovative topical formulation development and GMP manufacturing.

Key Points: 
  • With its rich dermatological heritage, NUVISAN France specializes in innovative topical formulation development and GMP manufacturing.
  • "NUVISAN is excited to work with such an inspiring biotech to accelerate the development of this innovative therapy.
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.
  • NUVISAN Group is a 1000+ employee CRO/CDMO (Contract Research Organization/Contract Development Manufacturing Organization) specialized in drug development.

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference

Retrieved on: 
Monday, February 7, 2022

NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 August 4, 2022 in San Diego, California.

Key Points: 
  • NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 August 4, 2022 in San Diego, California.
  • Dr. Carla Yuede, lead researcher on the HT-ALZ sponsored research agreement with Washington University , will be the primary author presenting the data.
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.
  • Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.

Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment

Retrieved on: 
Tuesday, February 1, 2022

Gb Science recently reported additional study data that supportsthe potential of cannabinoids as a treatment option for hyperinflammation resulting from COVID-19.

Key Points: 
  • Gb Science recently reported additional study data that supportsthe potential of cannabinoids as a treatment option for hyperinflammation resulting from COVID-19.
  • Gb Sciences and an MSU researcher evaluated the potential for cannabis-derived compounds to suppress immunological responses that contribute to COVID-19 symptoms.
  • Gb Sciences recently reported positive proof-of-concept data from this state-of-the-science human immune model studied at Michigan State University.
  • Gb Sciences' CCCM were designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key antiviral immune responses.